Efficacy of combined PD-1 immune therapy and chemotherapy in the treatment of locally advanced nonsmall cell lung cancer

Purpose: To investigate the clinical efficacy of anti-programmed cell death-1 (PD-1) immunotherapy in combination with chemotherapy patients suffering from locally advanced non-small lung cancer (NSCLC).
 Methods: A total 110 NSCLC admitted The Second Affiliated Hospital Hainan Medical University, Haikou, China were randomly divided into two groups using envelope method. control group was administered pemetrexed and cisplatin, study further treated nivolumab. Each treatment cycle lasted for 21 days, a 6 cycles duration therapy. short-term objective response rate, adverse reactions, programmed death5 (PDCD-5), tumor necrosis factor-α (TNF-α), factor-β1 (TGF-β1), immune status indices determined.
 Results: remission rate 79.25 % (42/53), which higher than that (61.40 %, 35/57; p < 0.05). After treatment, both showed levels PDCD5 TNF-α compared to their pre-treatment values, while demonstrating lower TGF-β1. Furthermore, PDCD-5 those group, TGF-β1 (p In values clusters differentiation 3+(CD3+), 4+(CD4+), 8+(CD8+) decreased after CD8+ increased treatment. CD3+, CD4+, CD4+/CD8+ 0.05).
 Conclusion: Anti-PD-1 local stabilizes system improves NSCLC. Further trials are, however, required prior application this practice.